Implantable stent for sinusitis
A technology of nasal passages and polymer materials, applied in the field of implantable stents for the treatment of sinusitis, can solve problems such as non-response to treatment
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0271] First, using PLGA(85:15) copolymer, a uniform braided scaffold was prepared by winding fiber spun monofilaments on individual bobbins (see, e.g. Figure 3A ). Each spool is placed on the braiding machine, taken up through the rollers and eyelets, and wound around a mandrel of desired OD (eg, 7, 8 or 10 mm). Set the braiding tension of the machine according to the size of the monofilament. In order to obtain a braid angle with optimum properties, including radial strength, weft yarns per inch (pix / inch) are set. A weaving pattern is selected and the monofilament is braided out of the coil onto the mandrel by the braiding machine. Winding tape is used at the end of each mandrel to maintain tension on the filaments, which can be used for thermal annealing and high modulus properties. The braided polymer is thermally annealed on the mandrel, then cut to the desired length with a blade, and removed from the mandrel.
Embodiment 2
[0276] The stent prepared in Example 1 was further coated with an additional conformal coating comprising a mixture of PLCL and mometasone furoate (MF) as the active agent. The PLCL in the MF-containing coating comprised approximately 70% (mol%) lactic acid, with the balance being caprolactone (PLCL 70:30). A homogeneous solution of MF and PLCL in dichloromethane (DCM) was prepared. Then, the DCM solution was sprayed on a 7 mm scaffold with 24 chains.
[0277] The amount of MF loaded per scaffold is controlled by the thickness and loading ratio of the MF-containing coating. By controlling the MF with a thickness between Figure 17B ).
Embodiment 3
[0279] To provide a more linear release profile, a topcoat comprising PLCL (70:30) and PLA was further coated on the drug-coated stent. A homogeneous solution of 0.75 wt% PLCL and 0.25 wt% PLA in DCM was prepared. Then, the DCM solution was sprayed on a 7mm scaffold with 24 chains in a single coat with variable coating passes to obtain different topcoat thicknesses. Such as Figure 18 As shown, the MF release was tuned by varying the thickness of the topcoat. The thicker the topping, the slower the drug release. Combining this approach with different drug loading ratios, different daily doses with programmable release durations are readily achievable.
PUM
| Property | Measurement | Unit |
|---|---|---|
| thickness | aaaaa | aaaaa |
| thickness | aaaaa | aaaaa |
| diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More